News | April 09, 2009

Gene Variant Associated with Diminished Effects of Clopidogrel in PCI Patients After One Year

April 9, 2009 - According to research presented last week at ACC, patients with the CYP2C19*2 genotype had more ischemic events in the one year following percutaneous coronary intervention (PCI).

A study was undertaken to link patients’ non-responsiveness to clopidogrel to the genetic variability of the Cytochrome P450 gene, or CYP2C19. The relation of the CYP2C19*2 variant to platelet function was measured through ADP-induced platelet aggregation and one-year cardiovascular outcomes in 227 patients using clopidogrel following traditional post-PCI procedures used to treat coronary heart disease. It was determined that those patients with the CYP2C19*2 genotype did in fact have more ischemic events in the one year following PCI.

The CYP2C19*2 variant is present in about 30 percent of the general U.S. population.

“This knowledge may enable physicians for the first time to improve individual antiplatelet management by a diagnostic approach utilizing platelet function or genetic testing,” said Paul A. Gurbel, M.D., lead author from the University of Maryland School of Medicine in Baltimore, Maryland. Patients with high platelet reactivity already on clopidogrel therapy may be offered alternative P2Y12 inhibitors that are either not prodrugs or a thienopyridine not highly dependent on CYP2C19 for metabolic activation. Alternatively, prior to institution of clopidogrel therapy, genetic testing may also lead to more selective use of these alternative agents.”

Dr. Gurbel presented the study “Influence of CYP2C19 Polymorphism on Antiplatelet Effects of Clopidogrel and Long-Term Recurrent Ischemic Event Occurrence” during the ACC in Orlando, FL.

For more information: www.acc.org

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init